Magenta Therapeutics Q3 net loss $16.1M; cash $128.3M funds into Q2 2024

Dianthus Therapeutics, Inc. /DE/

2022-Q3 EPS reported -$0.95 revenue$5,242,000

Cash, equivalents and marketable securities $128.3M at Sept 30, 2022, down from $176.9M at Dec 31, 2021.
Net loss of $16.1M for Q3 2022 vs $17.4M in Q3 2021; R&D expense $11.2M, G&A $6.1M.
MGTA-117 Phase 1/2 trial in AML/MDS progressing; no related SAEs or DLTs; Cohort 3 enrollment completed.
CD45-ADC toxicology study done; IND-enabling ongoing; program update expected Dec 2022.
MGTA-145 sickle cell trial enrolling; initial data anticipated Dec 2022, comprehensive data H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ reported financial results for third quarter ending September 30, 2022.

Period: third quarter ending September 30, 2022
Result: reported results

Exact text from the filing

Magenta Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-22-276477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.